TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2024, December 23 08:00 a.m. TME Pharma announces successful completion of Euro 2.6 million public offer with strong shareholder support 2024, December 20 06:00 p.m. TME Pharma provides results of fourth exercise of Warrants Z 2024, December 12 08:00 a.m. TME Pharma announces the launch of fully guaranteed public offer for Euro 2.6 million open only to shareholders to enable completion of strategic transactions by June 2025 |
EventsAllinvest Securities Biomed Forum
Aram Mangasarian, Ewelina Staniuk Latest Analyst ReportInvest Securities |